1h
News Medical on MSNIgE antibodies show promise in targeting HER2 cancers resistant to other therapiesAntibody treatment which activates the patient's own immune system against cancer, known as immunotherapy, is increasingly being investigated as an alternative for chemotherapy and radiotherapy.
Chronic rhinosinusitis with nasal polyps presents a substantial clinical burden, affecting nasal airflow, olfactory function, ...
VUMC received up to $30M to develop AI for antibody therapy discovery, aiming to create an antibody-antigen atlas and ...
Viruses like the one that causes COVID-19 constantly mutate, rendering many antibody treatments ineffective. A Stanford-led ...
17h
Pharmaceutical Technology on MSNWuXi XDC and AbTis collaborate on antibody-drug conjugatesThe partnership combines AbTis' AbClick site-selective conjugation platform with WuXi XDC's all-in-one development and ...
Complementing its antibody offerings, BosterBio provides a range of ELISA kits designed for quantitative detection of proteins, cytokines, and other biomarkers. These kits are widely used in drug ...
Could aspirin keep cancer from spreading? A new study from the University of Cambridge suggests that the common pain medication could have this surprise benefit. Experts weigh in.
3d
News Medical on MSNVanderbilt researchers aim to use AI to develop antibody therapies for any targetAn ambitious project led by Vanderbilt University Medical Center investigators aims to use artificial intelligence technologies to generate antibody therapies against any antigen target of interest.
Wexford-based biopharmaceutical company Coeptis Inc. announced the formation of GEAR Therapeutics, a majority-owned ...
ADCs are currently at the forefront of cancer treatment, but persistent drug development challenges call for a new approach.
Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new b ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results